Replies to post #427373 on NorthWest Biotherapeutics Inc (NWBO)

[KIPK]

The abstract says it all.

Automation to ensure Low Cost & Reproducible Manufacturing, capable of rapid expansion to meet demand is the key here & NWBO management very much aware of it obviously!!

That was the reason for the demise of DNDN!!

Stars have aligned!!

Very Long NWBO!!

[newman2021]

Thanks flipper; all your DDs are always strengthening our conviction in this stock as everyday moves closer to the reveal day. Parallel processing patent is this one I see. They can install multiple units and process parallelly now. MHRA Cert should be on its way now I guess.

[Know-Fear]

Thanks again, very cool. And I find especially intriguing quoted below..

Systems are configured to have multiple connected cell culture chambers, which allows parallel processing of different types of cells.

..does make one ponder the possibilities

[sukus]

These are so cool Flipper “greater scalability, flexibility, and automation. “

[flipper44]

Now that November 29, 2021 loan to accelerate NWBO’s brain cancer therapy program makes a lot more sense. Just 14 days after Shashi Murthy’s automated closed system patent allowance.

That’s twice now NWBO moved swiftly and decisively after two separate patent advancements.

1. Dendritic cell generator patented. NWBO acquires Flaskworks less than a month later and data locks trial a month after that.

2. Automated closed system for cell manufacturing —patent allowed. NWBO announces 15 million dollar loan 14 days later for the purpose of accelerating it brain cancer therapy program.

[Lykiri]

flipper44,

great work and thanks for sharing!

This makes future global market penetration manufacturing capacity a reality.*
(Assuming positive DC study result)

100% agree!

[biosectinvestor]

Excellent news and what I have suggested before it seems, that the manufacturing technology will be set-up for a factory, and will over time continuously improve in terms of efficiency and capacity.

[eagle8]

WOW flipper.
Very good news.
Thanks for sharing!

Best.

[hyperopia]

Thanks flipper, this patent is for Flaskworks’ BATON system, not the MicroDEN system that will be used for DCVax-L. The BATON system cultures two types of cells using two different culturing methods; dendritic cells in an adherent container, and T-cells in suspension. It was developed by Shashi Murthy to manufacture Neon Therapeutics’ neoantigen immunotherapy with his first grant from the National Science Foundation in 2016.

I’ve wondered if this system will be tailored and further developed to produce DCVax-Direct, which cultures the dendritic cells in suspension. I think I read somewhere that the company intends to develop the Flaskworks’ technology for DCVax-Direct, after development for DCVax-L has been completed.

BTW - This is the system that Shashi Murthy was making presentations about dendritic cell manufacturing systems at conferences like Phacilitate, where I believe he caught the attention of Linda Powers, who potentially encouraged the development of the MicroDEN system.


Shashi Murthy Wins NSF Grant for Cell Therapy Manufacturing with Neon Therapeutics
Via Northeastern | September 2, 2016

Chemical Engineering Professor Shashi Murthy has received funding from the National Science Foundation to develop novel manufacturing technologies for cell-based cancer therapies.  This project will be a collaborative effort with Cambridge, MA-based Neon Therapeutics which is developing neo-antigen-based therapeutic vaccines and cell-based therapies for cancer.  Cell-based therapies represent the next major frontier in the treatment of cancer and their personalized nature presents unique challenges in manufacturing.   This project brings together an interdisciplinary team of engineers and immunologists to design innovative automated bioreactors that can be optimized for biological function.  This grant provides $300,000 in funding over a two year period to be shared equally by Northeastern and Neon Therapeutics.

https://aimbe.org/college-of-fellows/COF-2015/


National Science Foundation
Award Abstract # 1645205
EAGER: Biomanufacturing: BATON: Bioreactor System for Autologous T-Cell Stimulation

https://nsf.gov/awardsearch/showAward?AWD_ID=1645205&HistoricalAwards=false